SS Innovations International, Inc. SSII PHARMA
Company Overview
SS Innovations International, Inc., together with its subsidiaries, operates as a commercial-stage surgical robotics company in India, Philippines, Indonesia, South America, Iraq, Cyprus, Oman, United Arab Emirates (UAE), Nepal, and internationally. It offers SSi Mantra, a surgical robotic system; and SSi Mudra, a range of stapling, energy, and core instrumentations for surgical systems. The company also develops NADI Automated Coronary Anastomotic Connector, a micro stapling device; SSi Multi-Fire Clip Applier, a cartridge-based clip applicator; SSi Robotic Stapler; SSi Maya is an enabling digital platform that compliments the SSI Mantra system and enhances surgical capabilities; SSi Guru is a virtual tele illustration; SSi XR Cognitive Skill Simulator is an extended reality (XR) software platform developed to train and educate surgeons and surgical assistants; SSi MantraM; SSi Mantra Tele Surgeon Console (TSC); and 5mm surgical instruments; SSi Holographic Anatomy, an augmented reality tool; SSi Chitrasa Advanced DICOM Viewer, an AI enabled application viewer; and SSi Mixed Reality Headset, a medical-grade device. In addition, it offers instrument tips, including forceps, scissors, electrocautery tools, scalpels, and other surgical tools. Further, the company provides accessory products, such as sterile drapes, 3d stereo endoscopes, cannulas, and seals, as well as tele proctoring and telesurgery products. Additionally, it offers installation, repair, maintenance, 24/7 technical support, and proactive health monitoring services. The company sells its products through direct sales organizations and distributor networks. SS Innovations International, Inc. is headquartered in Gurugram, India.
Why Investors Should Care
Revenue has grown at a 209.3% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.33.
Recent Developments
- Dec 2025 Revenue of $42.48M (+105.7% YoY); net profit $-12.13M.
- Trailing 12 Months Year-on-year growth — revenue +39.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 209.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 209.27% |
| 1 Year: | 39.40% |
Stock Price Performance
| 1 Year: | -49.69% |
| 6 Months: | -30.13% |
| 3 Months: | -7.37% |
| 1 Month: | -13.26% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)35.69 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 209.3% over 5 years.
CONS
- Trading 67.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SSII SS Innovations International, Inc. PHARMA | 3.27 | -54.50 | $655.26M | 0.00% | -17.08% | -26.06% | 209.27% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.64M | 4.51M | 4.39M | 5.12M | 10.00M | 12.83M | 14.53M | 11.10M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.03M | 4.09M | 6.66M | 8.16M | 5.77M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 511.18K | 224.16K | 16.12K | 728.18K | 1.44M | 2.32M | 1.09M | 5.92M | 6.16M | 6.38M | 5.33M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.01M | 5.82M | 8.00M | 7.11M | 8.97M |
| Operating Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -170.03K | -900.14K | -2.96M | -1.76M | -769.82K | -9.83M | -4.10M | -3.20M | -5.92M | 97.01K | -1.84M | -735.00K | -3.64M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.09M | 574.20K | -1.40M | -60.94K | -2.82M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 379.90K | 216.80K | 176.64K | 335.30K | 284.05K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.68M | 97.04K | -1.87M | -705.73K | -3.43M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 353.73K | 1.85M | 1.77M | 151.35K |
| Net Income | -43.24K | -246.87K | -196.31K | -187.38K | -180.07K | -238.40K | -205.51K | -297.27K | -395.48K | -539.00K | -1.40M | -307.01K | -220.30K | -375.53K | -300.06K | -412.31K | -418.21K | -80.42K | -170.00K | -790.10K | -2.99M | -1.85M | -1.22M | -9.84M | -4.14M | -3.25M | -5.68M | -256.69K | -3.72M | -2.47M | -3.58M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -0.01 | -0.01 | -0.02 | -0.01 | -0.02 | -0.02 | -0.00 | 0.00 | 0.00 | -0.05 | -0.01 | -0.01 | -0.06 | -0.02 | -0.02 | -0.03 | 0.00 | -0.02 | -0.01 | -0.02 |
| R&D Expense | 27.22K | 54.44K | 46.52K | 4.62K | 6.07K | 12.05K | 4.23K | 2.66K | 24.06K | 27.81K | 4.50K | 2.00K | - | - | - | 1.00K | - | - | - | - | 1.96K | - | 293.09K | 527.99K | 759.00K | 442.84K | 1.01M | 498.60K | 786.32K | - | 995.44K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 1.44M | 5.88M | 20.65M | 42.48M |
| Cost of Revenue | - | - | - | - | - | - | 1.38M | 5.15M | 12.20M | 22.94M |
| Gross Profit | - | - | - | - | - | - | 60.58K | 725.53K | 8.45M | 19.54M |
| Operating Expenses | - | - | - | - | - | - | 3.02M | 21.00M | 27.43M | 27.74M |
| Operating Income | - | - | - | - | - | - | -2.96M | -20.27M | -18.98M | -8.19M |
| EBITDA | - | - | - | - | - | - | -2.85M | -19.83M | -17.74M | -5.98M |
| Interest Expense | - | - | - | - | - | - | 265.52K | 894.62K | 973.24K | 1.11M |
| Pretax Income | - | - | - | - | - | - | -3.21M | -20.88M | -19.15M | -8.16M |
| Tax Provision | - | - | - | - | - | - | 0 | 0 | 0 | 3.97M |
| Net Income | -484.98K | -1.04M | -960.32K | -3.39M | -1.12M | - | -3.21M | -20.88M | -19.15M | -12.13M |
| Diluted EPS | - | - | - | -0.16 | -0.05 | - | -0.03 | -0.14 | -0.11 | -0.06 |
| R&D Expense | 127.58K | 71.17K | 27.12K | 60.87K | 3.00K | 1.00K | 83.28K | 1.06M | 2.49M | 3.69M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 292.23K | 509.96K | 145.43K | 132.52K | 317.87K | - | 6.98M | 31.52M | 42.39M | 74.23M |
| Current Assets | - | - | - | - | - | - | - | 4.10M | 21.43M | 27.42M | 48.80M |
| Cash & Equivalents | 100 | 248.22K | 452.57K | 35.72K | 28.47K | 160.71K | - | 217.18K | 2.02M | 466.50K | 3.21M |
| Inventory | - | - | - | - | - | - | - | 904.10K | 7.02M | 10.21M | 17.06M |
| Receivables | - | - | - | - | - | - | - | 156.86K | 1.90M | 4.47M | 12.40M |
| Total Liabilities | - | - | - | - | - | - | - | 9.66M | 11.80M | 28.93M | 36.01M |
| Current Liabilities | - | 647.29K | 408.87K | 368.47K | 1.20M | 1.19M | - | 7.77M | 8.47M | 21.33M | 26.24M |
| Long Term Debt | - | - | - | - | - | - | - | 469.02K | - | - | - |
| Total Debt | - | - | - | - | - | - | - | 8.27M | 9.28M | 18.20M | 14.36M |
| Total Equity | -66 | -355.06K | 101.09K | -223.04K | -1.06M | -869.05K | - | -2.68M | 19.72M | 13.46M | 38.22M |
| Shares Outstanding | - | - | - | - | - | - | - | 5.39M | 170.71M | 171.58M | 194.17M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -446.86K | -443.29K | -424.11K | -90.54K | - | -5.99M | -15.36M | -9.50M | -18.54M |
| Investing Cash Flow | -4.17K | -23.57K | -50.12K | -44.00K | - | 240.82K | -453.33K | -661.48K | -3.66M |
| Financing Cash Flow | 655.38K | 50.00K | 466.99K | 266.77K | - | 5.90M | 22.80M | 9.43M | 26.17M |
| Capital Expenditure | - | - | - | - | - | -220.32K | -453.33K | -661.48K | -3.66M |
| Free Cash Flow | - | - | - | - | - | -5.99M | -15.81M | -10.16M | -22.20M |
| Net Change in Cash | - | - | - | - | - | 142.50K | 6.98M | -738.53K | 3.96M |
| Share Buybacks | - | - | - | - | 26.00K | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | 4.2% | 12.3% | 40.9% | 46.0% |
| Operating Margin % | - | - | - | - | - | - | -206.0% | -345.1% | -91.9% | -19.3% |
| Net Margin % | - | - | - | - | - | - | -223.8% | -355.4% | -92.7% | -28.5% |
| ROE % | 136.6% | -1,026.5% | 430.6% | 318.5% | 129.4% | - | 120.0% | -105.9% | -142.3% | -31.7% |
| ROCE % | - | - | - | - | - | - | 376.6% | -88.0% | -90.1% | -17.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Hood River Capital Management LLC | 0.43% | 833.33K | $2.72M |
| 2 | Inspire Investing, LLC | 0.10% | 186.30K | $607.33K |
| 3 | Handelsbanken Fonder AB | 0.06% | 120.00K | $391.20K |
| 4 | Eversept Partners, LP | 0.06% | 110.16K | $359.11K |
| 5 | JNBA Financial Advisors | 0.05% | 102.29K | $333.47K |
| 6 | AlphaCentric Advisors LLC | 0.03% | 50.00K | $163.00K |
| 7 | UBS Group AG | 0.03% | 51.21K | $166.94K |
| 8 | Forum Financial Management, LP | 0.02% | 38.47K | $125.41K |
| 9 | Geode Capital Management, LLC | 0.02% | 41.77K | $136.17K |
| 10 | Alti Global, Inc. | 0.01% | 20.55K | $67.01K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SSII
SS Innovations International (SSII) Stock Rich Valuation Meets Rising Losses - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNek5LS19paFE2aE9XLWo1bWYza1VFMWZkUDdRNmtITC1IWno2LTB6Z2dyQndzVWR4NkpFLTM3RlhqU1BQYlJCRklPWUF0X0tRZkxUX29ueFpROHA1clpFOTZWaHJKdGpLTF9KMTRxOHBBcGxsaC1EY3lLT2stdU85UDJsMXFFSGJxVzVsYT…
SS Innovations International (NASDAQ: SSII) Turning India’s Surgical Robotics Opportunity Into a Global G - Benzinga
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPTFVkclM1VmhUM2NnLWNGSUtNQnVMY2J0RU5DU3pSOTdKYzE2SXNDcThkeWRaa3pmTjVEeVdUbTZSbzFWaW9WX0tmOVBTc1RPdEpYMlZEeVNxNjVqVlBqU211YkxSbnlTR3NEUk96Y2hkYjZ5eG82NjBnMDBoUWR4VHBIYVI1V256b2hLRT…
SS Innovations Installs 30 SSi Mantra Surgical Systems in Q2 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPblAxa3NNVlpsa0YtbHhWWUxoaDBXb00tallNVklCY2FhNXVNVG0yV2NJaDRFSnA0ME8yWGhUNzVfd0o0WGhtUlZvcEdSY2k5U2JEc0VGLU5FcHFsV1h0S21fbl85aDlDRkUwOWhfV3NsSWhaZUV1dmU2UDBMdTBfVmFvakxvcmdieV9GR0…
SSII - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5TMUNmZ2ozelB3M3VXTGlKQkEwcmJDSXdLTlR3TDUyY1lMdWtFcXF1X1F5VUkwdGFkcUZtczZoU2xiYnljNVE?oc=5" target="_blank">SSII</a> <font color="#6f6f6f">Finviz</font>…
SS Innovations International (NASDAQ: SSII) Highlighted as Stronger Growth Opportunity in Seeking Alpha Analysis - Barchart.com
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxPc3VYSUlyRDNZYmNkcktSRXBzUlZ6UWZNYllCSU9qRDV4QVNKUGcwV3N2REtkcEtFZzRrc2EycHBuTnQzV1R4VmZWTmV5RG44V00zQUl5OVgyZ3BVUzluSnBhS1o5b09PVlBKWnE1TUtvb1BnMTAwcVdLRUlVN0dSUm42ZFVZVDVkMF9Qcz…
SS Innovations Revenue Rises 39% to $13.9 Million in Second Quarter - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOYlNsSHlOdmhOWENnNW1sMFNsTm1WdVZQcHdVeWwydlc3U0FwUFVDaTVWQlo1WTlIR0VWUVJOUndOM0hVVUVoM1VSWXhteTJLMEhma1lzUU5wT053S0ZTX3VtdzE0eXo0ZXRPTjdjd3JJZFZxS1o0ckVZbmVfNnpuYnZueHpfcnkwZElpQk…
SSII — Frequently Asked Questions
What is the current share price of SS Innovations International, Inc. (SSII)?
As of 2026-09-19 21:16 PDT, SS Innovations International, Inc. (SSII) trades at $3.27 on NasdaqCM. Its 52-week range is $3.27 to $9.98.
What is the market capitalisation of SSII?
SS Innovations International, Inc. (SSII) has a market capitalisation of $655.26M on NasdaqCM.
What is the P/E ratio of SSII?
SSII trades at a trailing price-to-earnings (P/E) ratio of -54.50. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 11.99.
What is the return on equity (ROE) of SSII?
SSII has a return on equity (ROE) of -26.06%. Its return on capital employed (ROCE) is -17.08%.
Is SSII a good stock to buy?
This page provides a data-driven analysis of SS Innovations International, Inc. (SSII), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.